InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Grandbrothers

• The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).
• PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs.
• The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release.
• Vilobelimab has already received orphan drug status for PG in the U.S. and EU.
• IFRX +14.08% to $1.62 premarket July 6